DrugPatentWatch Database Preview
Sunovion Resp Company Profile
What is the competitive landscape for SUNOVION RESP, and when can generic versions of SUNOVION RESP drugs launch?
SUNOVION RESP has one approved drug.
There are ten US patents protecting SUNOVION RESP drugs.
There are seventy-two patent family members on SUNOVION RESP drugs in thirteen countries and one supplementary protection certificate in one country.
Summary for Sunovion Resp
| International Patents: | 72 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Sunovion Resp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | 9,604,018 | Start Trial | Y | Start Trial | |||
| Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | 6,962,151 | Start Trial | Y | Start Trial | |||
| Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | 9,168,556 | Start Trial | Y | Start Trial | |||
| Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | 9,265,900 | Start Trial | Y | Start Trial | |||
| Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | 7,931,212 | Start Trial | Y | Start Trial | |||
| Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | 9,789,270 | Start Trial | Y | Start Trial | |||
| Sunovion Resp | LONHALA MAGNAIR KIT | glycopyrrolate | SOLUTION;INHALATION | 208437-001 | Dec 5, 2017 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Sunovion Resp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 518782 | Start Trial |
| Japan | 2012213641 | Start Trial |
| European Patent Office | 2895136 | Start Trial |
| Spain | 2552641 | Start Trial |
| Japan | 4589862 | Start Trial |
| Germany | 60039902 | Start Trial |
| Brazil | PI0614818 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sunovion Resp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2435025 | 2019C/532 | Belgium | Start Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
